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Background: Primary androgen deprivation therapy (PADT) is the most effective systemic therapy for patients
with metastatic prostate cancer. Nevertheless, once PSA progression develops, the prognosis is serious and mortal.
We sought to identify factors that predicted the prognosis in a series of patients with metastatic prostate cancer.
Methods: Two-hundred eighty-six metastatic prostate cancer patients who received PADT from 1998 to 2005 in
Nara Uro-Oncology Research Group were enrolled. The log-rank test and Cox’s proportional hazards model were
used to determine the predictive factors for prognosis; rate of castration-resistant prostate cancer (CRPC) and overall
survival.
Results: The median age, follow-up period and PSA level at diagnosis were 73 years, 47 months and 174 ng/
mL, respectively. The 5-year overall survival rate was 63.0%. The multivariable analysis showed that Gleason
score (Hazard ratio [HR]:1.362; 95% confidence interval [C.I.], 1.023-1.813), nadir PSA (HR:6.332; 95% C.I.,
4.006-9.861) and time from PADT to nadir (HR:4.408; 95% C.I., 3.099-6.271) were independent prognostic
factors of the incidence of CRPC. The independent parameters in the multivariate analysis that predicted
overall survival were nadir PSA (HR:5.221; 95% C.I., 2.757-9.889) and time from PADT to nadir (HR:4.008; 95%
C.I., 2.137-7.517).
Conclusions: Nadir PSA and time from PADT to nadir were factors that affect both CRPC and overall survival in a
cohort of patients with metastatic prostate cancer. Lower nadir PSA level and longer time from PADT to nadir
were good for survival and progression.
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Prostate cancer is the fourth most commonly diagnosed
cancer and the ninth leading cause of cancer deaths among
males in Japan [1]. At the moment, Japanese prostate can-
cer patients show higher risk characteristics compared with
the patients in the United States, and the proportion of
metastatic patients is still high [2,3]. Whereas primary
androgen deprivation therapy (PADT) is standard for meta-
static prostate cancer, most patients progress to castration-
resistant prostate cancer (CRPC) at various intervals after
PADT. Prostate specific antigen (PSA) is a biomarker for* Correspondence: tomioka515@yahoo.co.jp
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unless otherwise stated.diagnosis, risk classification, and monitoring of the disease.
Most patients will experience a substantial decline in PSA
levels, and their PSA levels may remain low or undetectable
for years. Nevertheless, CRPC occurs frequently [4]. CRPC
follows an androgen-independent state, which leads to
widespread metastases. PSA progression in advanced pros-
tate cancer indicates clinical progression in patients treated
with PADT within a median of 6 months [5]. The substan-
tial variability in the clinical course of metastatic prostate
cancer has led to the evaluation of a number of prognostic
factors with respect to their roles in determining the treat-
ment strategy and ability to predict the response to therapy.
In most clinical trials of prostate cancer, an improve-
ment of 50% in the serum PSA is used as a marker ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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when using changes in PSA is defined by the Prostate
Cancer Clinical Trials Working Group (PCWG2) [6]
and the Prostate-Specific Antigen Working Group
(PSAWG) [7], and has been validated by the data-sets
from two large Southwest Oncology Group Trials
(SWOG 9346 and 9916) [8]. We endeavored to identify
risk factors for prognosis in our series of patients with
hormone naïve metastatic prostate cancer.
Methods
This study retrospectively evaluated 286 Japanese pa-
tients with metastatic prostate cancer who received
PADT following diagnosis in the Nara Uro-Oncology
Research Group (NUORG) between January 1998 and
December 2005. The diagnosis was based on prostate
biopsy. Abdominal computed tomography and/or bone
scans were used in all cases with suspected metastases.
All patients were treated with PADT using a luteinizing
hormone-releasing hormone (LH-RH) agonist, surgical
castration, anti-androgen monotherapy or combined
androgen blockade (CAB).
Follow-up data were retrieved from the hospital medical
records. Patients were followed every month for the first
3 months and every 3 months thereafter. The nadir PSA
level was defined as the lowest PSA level after PADT.
CRPC was defined as the first day when the PSA was in-
creased for three consecutive times or when clear clinical
radiological evidence of progressive disease was shown.
This study analyzed the incidences of progression times to
CRPC after the initiation of PADT and overall survival
time. The progression rate to CRPC and overall survival
rate were estimated and both univariate and multivariate
analyses were carried out to determine the prognostic
value of age (≤75 years vs. ≥76 years), TNM classification
(UICC 2002 [9]), pathological Gleason score (6–8 vs. 9–10),
PSA level at diagnosis (<100 ng/mL vs. 100–500 ng/mL
vs. ≥500 ng/mL), nadir PSA level (<0.2 ng/mL vs. 0.2-
4 ng/mL vs. ≥4 ng/mL), time from PADT to nadir
(≥12 months vs. 6–12 months vs. <6 months) and time from
PADT to CRPC (No occurrence of CRPC vs. ≥12 months vs.
6–12 months vs. <6 months).
Statistical analyses were carried out using the SPSS
software package (SPSS Inc., Chicago, Illinois, version
17.0) and p < 0.05 was considered to be statistically sig-
nificant. Overall survival was estimated by the Kaplan-
Meier method. The log rank test was used to assess
differences between groups. The Cox proportional hazards
regression model was performed to analyze independent
predictors of CRPC and overall survival. Only the variables
that were found to be significant in the univariate analyses
(p < 0.05) were entered into the multivariate analysis to de-
termine the most significant factor for predicting disease
outcome.The Medical Ethics Committee of Nara Medical Uni-
versity approved this retrospective study, and it was
exempted to obtain informed consent from the patients
in consideration of the aim and methods of this study.Results
The characteristics of the patients are shown in Table 1.
The median age and PSA at diagnosis were 73 years
(range 50 to 92) and 174 ng/mL (range 5.7 to 21864), re-
spectively. The median follow-up was 47 months (range 2
to 128) and the treatment of PADT was CAB in 92.0% of
the patients. There were no differences in the progression
time to CRPC and overall survival between PADTs (LH-
RH agonist, surgical castration, anti-androgen monother-
apy or CAB) (Data are not shown). Most patients initially
responded to PADT. The median nadir PSA level was
0.3 ng/mL (range 0.001 to 650) and 42.7% of patients
reached a nadir PSA <0.2 ng/mL. The median time from
PADT to nadir was 9.45 months (range 1 to 64). 72.4% of
patients progressed to CRPC and the median time to pro-
gression after the initiation of treatment was 13 months
(range 1 to 97). The 5-year overall survival rate was 63.0%,
the median survival time from CRPC was 45 months, and
35.7% of patients died during the follow-up period, of
which cancer deaths and other cause deaths were 27.6%
and 8.0%, respectively.
T stage (T2 vs. T3, T4), Gleason score (6–8 vs. 9–10),
PSA at diagnosis (<100 ng/mL vs. ≥500 ng/mL),
nadir PSA (<0.2 ng/mL vs. 0.2-4 ng/mL) and time
from PADT to nadir (≥12 months vs. 6–12 months vs.
<6 months) were significantly associated with the progres-
sion time to CRPC (Table 1). A lower nadir PSA level and
a longer time from PADT to nadir were associated with a
lower proportion of patients with CRPC progression. The
median progression time to CRPC of the patients with
nadir PSA <0.2 ng/mL, 0.2-4 ng/mL and ≥4 ng/mL were
38 months, 13 months and 8 months, respectively (p < 0.005).
The median progression time to CRPC of the patients
whose time from PADT to nadir were ≥12 months, 6-12
months and <6 months, were 35 months, 13 months and
7 months, respectively (p < 0.005). The median nadir
PSA level of the patients with time from PADT to nadir
≥12 months, 6–12 months and <6 months, were 0.1 ng/
mL, 0.3 ng/mL and 1.18 ng/mL, respectively (p < 0.05:
≥12 months vs. <6 months). The univariate analysis
showed that the Gleason score, PSA at diagnosis, nadir
PSA and time from PADT to nadir were associated with
progression to CRPC (Table 2). The multivariate analysis
showed that Gleason score, nadir PSA and time from
PADT to nadir were significant independent factors.
The log-rank test showed that overall survival was
correlated with nadir PSA (<0.2 ng/mL vs. 0.2-4 ng/mL
vs. ≥4 ng/mL), time from PADT to nadir (≥12 months









No. of deaths Median survival
time (months)
Total 286 207 19 102 113
Age 73 (50–91)
≤75 179 132 19 69 85
≥76 107 75 18 n.s. 33 none n.s.
T T1 4 2 57
*(T2 vs. T3, T4)
0 all alive
T2 31 18 37 9 111
T3 162 114 19 60 83
T4 89 73 14 33 77 n.s.
N N0 164 116 19 59 79
N1 122 91 19 n.s. 43 99 n.s.
M M0 50 31 26 9 99
M1 236 176 18 n.s. 93 83 n.s.
Gleason score 6-8 181 83 21
*
63 115
9-10 105 124 14 39 85 n.s.
PSA at diagnosis 174 (5.7-21864)
<100 105 64 23
*(<100 vs. ≥500)
31 85
100-500 97 73 16 36 113
≥500 84 70 15 35 none n.s.
Nadir PSA level 0.3 (0.001-650)
<0.2 122 71 38
**
26 115
***0.2-4 112 86 13 44 62




≥12 114 74 35
**
23 113
***6-12 83 62 13 39 79




No CRPC 79 14 none
≥12 112 32 113 ***
6-12 63 34 35
<6 32 22 21
*P<0.005, **all P<0.001, ***P<0.001 without No CRPC vs. ≥12
PADT: primary androgen deprivation therapy.
CRPC: castration resistant prostate cancer.
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to CRPC (≥12 months vs. 6–12 months vs. <6 months)
(Table 1). The multivariate analysis showed that nadir
PSA and time from PADT to nadir were independent
factors associated with overall survival (Table 3).
Discussion
A PSA test provides useful information, not only for the
screening of prostate cancer but also for monitoring fol-
lowing treatment. Moreover, PSA monitoring before andafter PADT are useful to evaluate the response to treat-
ment in patients with prostate cancer. PSA concentrations
decrease by 80% in approximately 80% of patients in the
first month following PADT [10], and normalize in 95% of
cases within 3–6 months [11]. Rising PSA after the nadir
value under PADT represents the first objective sign of
CRPC. PSA recurrence usually predates clinical progres-
sion of metastatic prostatic cancer after PADT [6,12]. Most
of the patients in the current series initially responded to
PADT; 43.2% of patients reached a nadir PSA <0.2 ng/mL,
Table 2 Hazards ratio estimate and confidence intervals from proportional hazards modeling of progression to CRPC
Univariate analysis Multivariate analysis
Hazard ratio 95% C.I. P value Hazard ratio 95% C.I. P value
Age 0.993 0.975-1.011 0.425 0.990 0.972-1.007 0.248
T T1 1
T2 1.359 0.315-5.867 0.681
T3 2.142 0.528-8.691 0.286
T4 3.336 0.816-13.647 0.094
Gleason score 6-8 1 1
9-10 1.518 1.148-2.009 0.003 1.362 1.023-1.813 0.034
PSA at diagnosis <100 1 1
100-500 1.374 0.981-1.923 0.064 0.990 0.691-1.417 0.955
≥500 1.616 1.149-2.271 0.006 1.099 0.682-1.492 0.965
Nadir PSA level <0.2 1 1
0.2-4 2.778 2.011-3.836 <0.001 2.794 1.984-3.936 <0.001
≥4 6.339 4.315-9.313 <0.001 6.332 4.066-9.861 <0.001
Time from PADT to nadir ≥12 1 1
6-12 2.091 1.480-2.953 <0.001 2.245 1.559-3.232 <0.001
<6 4.131 2.956-5.774 <0.001 4.408 3.099-6.271 <0.001
95% CI.: 95% confidence interval.
PADT: primary androgen deprivation therapy.
CRPC: castration resistant prostate cancer.
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PADT to CRPC was 13 months.
We sought to identify risk factors for the prognosis of a
series of patients with metastatic prostate cancer before or
during PADT. We believe that it could be useful to decide
on the best treatment strategy to predict which patients
are more likely to develop early progression to CRPC.
There are many views about the prognostic value of the
PSA level at diagnosis. Several PSA-related parametersTable 3 Hazards ratio estimate and confidence intervals from
Univariate an
Hazard ratio 95% C
Age 0.987 0.962-1
Nadir PSA level <0.2 1
0.2-4 3.038 1.852-4
≥4 7 4.109-11
Time from PADT to nadir ≥12 1
6-12 2.544 1.473-4
<6 6.918 4.174-11




95% CI.: 95% confidence interval.
PADT: primary androgen deprivation therapy.
CRPC: castration resistant prostate cancer.have been reported, including PSA at diagnosis, pattern of
PSA decrease after treatment, time to nadir PSA and per-
centage of PSA decrease. Some authors found that the
PSA level at diagnosis did not predict the time to progres-
sion [5,13]. However, others have proposed that PSA at
diagnosis predicts the disease response to androgen sup-
pression [14-16]. Early normalization of PSA delays the
time to progression, and in combination with the Gleason
score, PSA is an important prognostic factor to predict theproportional hazards modeling of overall survival
alysis Multivariate analysis
.I. P value Hazard ratio 95% C.I. P value
.013 0.324 0.994 0.967-1.021 0.647
1
.982 <0.001 2.329 1.342-4.040 0.003
.925 <0.001 5.221 2.757-9.889 <0.001
1
.393 0.001 1.483 0.789-2.789 0.221
.467 <0.001 4.008 2.137-7.517 <0.001
1
.822 0.907 0.718 0.367-1.407 0.335
.089 <0.001 1.419 0.664-3.031 0.367
.808 <0.001 1.712 0.731-4.005 0.215
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after the initiation of PADT within 3 months is thought to
be more important than the Gleason score in determining
the time to progression [17].
Nadir PSA after PADT is usually evaluated in relation
to progression to CRPC [13,16,18-21]. The ability to
achieve an undetectable PSA level as nadir is the most
significant predictor of the time to CRPC for metastatic
and advanced prostatic cancer and the time to nadir
PSA is significantly and positively correlated with the
PSA progression-free survival [13]. Failure to attain a
nadir PSA of <1 ng/mL after treatment predicts early
progression to CRPC [20,21]. In the current series, the
median nadir PSA level was 0.3 ng/mL. We classify the nadir
PSA level into <0.2 ng/mL, 0.2-4 ng/mL and ≥4 ng/mL, be-
cause PSA level <0.2 ng/mL is an undetectable PSA and the
normal PSA value is less than 4 ng/mL. Then, nadir PSA
(<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL) was a significant
independent factor that predicted the progression to CRPC
after PADT.
Nadir PSA levels after PADTare usually evaluated in rela-
tionship to the overall survival time. A nadir PSA of >2 ng/
mL predicts poorer overall survival [21]. By using the data
of a randomized phase 3 trial, a PSA level of ≤4 ng/mL after
7 months of PADT was a strong independent predictor
of improvement survival in metastatic hormone-sensitive
prostate cancer [22]. Time to nadir < 6 months, Gleason
score >7 and nadir PSA ≥0.2 ng/mL independently pre-
dicted shorter overall survival in patients with metastatic
hormone-sensitive prostate cancer [18], which included pa-
tients who underwent definitive initial local therapy (rad-
ical prostatectomy or radiotherapy) and did not showed
the factor of time to CRPC after initiation of PADT. Nadir
PSA <0.2 ng/mL and longer time to nadir (>9 months)
during PADT are the most important early predictors for
survival in prostate cancer patients with bone metastasis
[23]. The current study included the metastatic prostate
cancer patients treated only with PADT, also predicts the
factor of progression to CRPC and showed a nadir PSA
(<0.2 ng/mL vs. 0.2-4 ng/mL vs. ≥4 ng/mL) and the
time from PADT to nadir (≥12 months vs. 6–12 months
vs. <6 months) were independent factors for overall sur-
vival. Nadir PSA and time from PADT to nadir are im-
portant factors associated with both CRPC and overall
survival. This indicates that a simple measurement of PSA
was strongly associated with time to CRPC and overall
survival in metastatic CRPC, and the optimal cut-off point
of the nadir PSA and the time from PADT to nadir pre-
dicts a short or long response of PADT.
Longer time to reach nadir PSA was associated with a
lower nadir PSA level and this may simply indicate con-
tinued androgen sensitivity. The mechanisms respon-
sible for the association of shorter time to nadir with
a worse prognosis are not clear. A rapid decrease in thePSA level may be related to a transcriptional effect of
PADT on PSA progression rather than prostate cancer cell
death [20]. A rapid decrease in the PSA level after PADT
may be due to ablation of the androgen receptor function,
and quick suppression of androgen/androgen receptor
during PADT may have a negative effect on disease pro-
gression, because the androgen receptor can act as a tumor
suppressor for prostate cancer [24]. Another possibility is
that a rapid removal of hormone-sensitive prostate cancer
cells may induce an environment that allows the growth of
hormone-resistant prostate cancer cells [23].
There are limitations to the current study. Firstly, some
important factors, such as lactate dehydrogenase, alkaline
phosphatase, albumin, testosterone, hemoglobin and per-
formance status were not included in this analysis, because
they were not routinely measured in the patients. Sec-
ondly, we only reported the outcomes of PADT but not
evaluated the following results of second-line treatment
such as chemotherapy. Thirdly, there may be interob-
server variation of the Gleason score between general pa-
thologists and uropathologists.
Conclusions
PSA progression and PSA decline provide clinically mean-
ingful information early during the treatment course of pa-
tients with metastatic prostate cancer who are unlikely to
benefit from standard PADT long before they develop
CRPC. Further prospective data and external validation of
independent datasets are needed to confirm these findings.
Lower nadir PSA value and longer time to nadir PSA
after the initiation of PADT correlate with lower progres-
sion to CRPC and higher overall survival.
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